Profil bibliographique

Michele Iudici

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

155Publications signalées

2665Citations signalées

3Affiliations récentes

Institutions déclarées

Hôpital Beau-Séjour University Hospital of Geneva Geneva College

Domaines associés

Systemic Sclerosis and Related DiseasesVasculitis and related conditionsInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisInflammatory Myopathies and DermatomyositisSystemic Lupus Erythematosus Research

Publications récentes

Accès ouvert 2026 conference-paperOpenAlex

P.041 Demographic and clinical features of systemic sclerosis patients with anti-U1RNP antibodies: a European scleroderma trials and research (EUSTAR) analysis

Wanlong Wu, Madeleine Venables, Eric Hachulla, Liala Moschetti et autres

0 citationsPoster presentations

Accès ouvert 2026 articleOpenAlex

Beyond screening for pulmonary arterial hypertension: The DETECT score is a potential promising prediction tool for all-cause mortality in systemic sclerosis: Analysis from the EUSTAR database

Florian Käs, Muriel Elhaï, Mike O. Becker, Rucsandra Dobrota et autres

0 citationsJournal of Autoimmunity

2026 letterOpenAlex

Reply

Anna Maria Vettori, Michele Iudici

0 citationsArthritis Care & Research

Accès ouvert 2025 articleOpenAlex

Overlapping forms of granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis: Insights from a European multicenter study

Federica Pallotti, C. Mettler, Matthias Papo, Michele Iudici et autres

2 citationsJournal of Internal Medicine

Accès ouvert 2025 articleOpenAlex

Beyond human gold standards: A multimodel framework for automated abstract classification and information extraction

Delphine S. Courvoisier, Diana Buitrago‐García, Clément P. Buclin, Nils Bürgisser et autres

1 citationResearch Synthesis Methods

Accès ouvert 2025 articleOpenAlex

Trends in Patient Accrual Rates, Screening Failures, and Related Reasons in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Randomized Controlled Trials

Michele Iudici, Barbara Russo, Xavier Puéchal

0 citationsThe Journal of Rheumatology

Accès ouvert 2025 articleOpenAlex

Concordance between presenting features and relapse in granulomatosis with polyangiitis: implications for risk assessment and counselling

Michele Iudici, Zübeyir Salis, Pascal Cohen, Antoine Néel et autres

1 citationRMD Open

Accès ouvert 2025 articleOpenAlex

Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort

Stefano Di Donato, John D Pauling, Sheila Ramjug, Yannick Allanore et autres

9 citationsLara D. Veeken

Accès ouvert 2025 conference-abstractOpenAlex

POS0266 DEVELOPMENT OF AN ARTICULAR SCORE IN SYSTEMIC SCLEROSIS (ASSESS): IDENTIFICATION OF CORE INSTRUMENTS TO ASSESS DISEASE ACTIVITY

B. Burja, P.M. Welsing, Alain Lescoat, A. Eisenring et autres

0 citationsAnnals of the Rheumatic Diseases

Accès ouvert 2025 conference-abstractOpenAlex

OP0082 Evidence-based detection of progression of systemic sclerosis-interstitial lung disease patients: the EUSTAR-PPF study (CP number 148)

C. Campochiaro, Denis Mongin, Delphine S. Courvoisier, P. Carreira Delgado et autres

1 citationAnnals of the Rheumatic Diseases

Accès ouvert 2025 conference-abstractOpenAlex

POS0571 Trial-level factors affecting accrual rate of systemic sclerosis randomized clinical trials

Barbara Russo, I.S. Chirică, D. Courvoisier, Michele Iudici

0 citationsAnnals of the Rheumatic Diseases

Accès ouvert 2025 conference-abstractOpenAlex

OP0332 WHAT WE KNOW ABOUT THE USE OF GLUCOCORTICOIDS IN SYSTEMIC SCLEROSIS RANDOMIZED TRIALS

I.S. Chirică, Barbara Russo, Michele Iudici

0 citationsAnnals of the Rheumatic Diseases

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.